Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 3/20 | 0.44 |
| ▸ | ADORA1 | P30542 | 3/20 | 0.44 |
| ▸ | GSK3B | P49841 | 11/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.42 |
| ▸ | CDK2 | P24941 | 4/20 | 0.42 |
| ▸ | CDK1 | P06493 | 3/20 | 0.42 |
| ▸ | CDK5 | Q00535 | 3/20 | 0.42 |
| ▸ | DYRK1A | Q13627 | 3/20 | 0.42 |
| ▸ | CLK4 | Q9HAZ1 | 3/20 | 0.42 |
| ▸ | MAP4K4 | O95819 | 2/20 | 0.42 |
| ▸ | LIMK1 | P53667 | 2/20 | 0.42 |
| ▸ | GSK3A | P49840 | 1/20 | 0.42 |
| ▸ | STK17A | Q9UEE5 | 1/20 | 0.42 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.41 |
| ▸ | FLT4 | P35916 | 2/20 | 0.41 |
| ▸ | MAPK8 | P45983 | 2/20 | 0.41 |
| ▸ | CLK2 | P49760 | 2/20 | 0.41 |
| ▸ | TAOK1 | Q7L7X3 | 2/20 | 0.41 |
| ▸ | SLK | Q9H2G2 | 2/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18325610 | 0.88 | XDH (0.50) | MAPK1ALDH1A1 | |
| SCHEMBL2221557 | 0.87 | ADORA3 (0.41) | ADORA2AADORA1CYP1A2ADORA3MAPK1 | |
| SCHEMBL31260667 | 0.86 | ALDH1A1 (0.45) | ADORA1GSK3BCYP1A2CDK2CDK1 | |
| SCHEMBL18325670 | 0.82 | XDH (0.39) | — | |
| SCHEMBL7905802 | 0.81 | HDAC1 (0.49) | — | |
| SCHEMBL1225985 | 0.78 | GDA (0.36) | ADORA2ACYP1A2DYRK1AADORA3ALDH1A1 | |
| SCHEMBL7062391 | 0.78 | LMNA (0.42) | CYP1A2MAPK1CSNK2A1TP53ALDH1A1 | |
| SCHEMBL7063733 | 0.77 | ALDH1A1 (0.43) | CYP1A2ADORA3MAPK1ALDH1A1 | |
| SCHEMBL7064550 | 0.76 | LMNA (0.47) | CYP1A2MAPK1NPSR1ALDH1A1 | |
| SCHEMBL2440388 | 0.75 | LMNA (0.52) | CYP1A2MAPK1CSNK2A1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6600044-B2 | Such as cis-(-)-4-amino-1-(2-(hydroxymethyl)-1,3-oxathiolan-5-yl)-2(1H)-pyrimidinone (lamivudine, 3TC) or emtricitabine via anomerization/transglycosylation | BRANTFORD CHEMICALS INC. | 2003-07-29 | — | — | US | disclosed |
| US-20030013880-A1 | Process for recovery of the desired cis-1,3-oxathiolane nucleosides from their undesired trans-isomers | APOTEX PHARMACHEM INC (CA) | 2003-01-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030013880-A1 | Process for recovery of the desired cis-1,3-oxathiolane nucleosides from their undesired trans-isomers | SLC29A1, NUDT1, SLC28A1 | ADORA2A 100/4885ADORA1 62/4885GSK3B 878/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.